The University of Notre Dame Australia

ResearchOnline@ND
Medical Papers and Journal Articles

School of Medicine

2016

Assessing the feasibility of a web-based registry for multiple orphan lung
diseases: The Australasian registry network for orphan lung disease
(ARNOLD) experience
K Casamento
A Laverty
M Wilsher
J Twiss
E Gabbay
University of Notre Dame Australia, Eli.Gabbay@nd.edu.au

See next page for additional authors

Follow this and additional works at: https://researchonline.nd.edu.au/med_article
Part of the Medicine and Health Sciences Commons
This article was originally published as:
Casamento, K., Laverty, A., Wilsher, M., Twiss, J., Gabbay, E., Glaspole, I., & Jaffe, A. (2016). Assessing the feasibility of a web-based
registry for multiple orphan lung diseases: The Australasian registry network for orphan lung disease (ARNOLD) experience.
Orphanet Journal Of Rare Diseases, 11 (42).
Original article available here:
http://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0389-z

This article is posted on ResearchOnline@ND at
https://researchonline.nd.edu.au/med_article/745. For more
information, please contact researchonline@nd.edu.au.

Authors
K Casamento, A Laverty, M Wilsher, J Twiss, E Gabbay, I Glaspole, and A Jaffe

This article is available at ResearchOnline@ND: https://researchonline.nd.edu.au/med_article/745

This article was originally published at:
http://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0389-z
Casamento, K., Laverty, A., Wilsher, M., Twiss, J., Gabbay, E., Glaspole, A., and Jaffe, A. (2016)
Assessing the feasibility of a web-based registry for multiple orphan lung diseases: the Australasian
Registry Network for Orphan Lung Disease (ARNOLD) experience. Orphanet Journal of Rare Diseases,
11(42). doi: 10.1186/s13023-016-0389-z
This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.

Casamento et al. Orphanet Journal of Rare Diseases (2016) 11:42
DOI 10.1186/s13023-016-0389-z

RESEARCH

Open Access

Assessing the feasibility of a web-based
registry for multiple orphan lung diseases:
the Australasian Registry Network for
Orphan Lung Disease (ARNOLD) experience
K. Casamento1*, A. Laverty2, M. Wilsher3, J. Twiss4, E. Gabbay5, I. Glaspole6,7, A. Jaffe8,9 and On behalf the Pulmonary
Interstitial Vascular Organisational Taskforce (PIVOT) of the Lung Foundation Australia

Abstract
Background: We investigated the feasibility of using an online registry to provide prevalence data for multiple
orphan lung diseases in Australia and New Zealand.
Methods: A web-based registry, The Australasian Registry Network of Orphan Lung Diseases (ARNOLD) was
developed based on the existing British Paediatric Orphan Lung Disease Registry. All adult and paediatric
respiratory physicians who were members of the Thoracic Society of Australia and New Zealand in Australia
and New Zealand were sent regular emails between July 2009 and June 2014 requesting information on
patients they had seen with any of 30 rare lung diseases. Prevalence rates were calculated using population
statistics.
Results: Emails were sent to 649 Australian respiratory physicians and 65 in New Zealand. 231 (32.4 %) physicians
responded to emails a total of 1554 times (average 7.6 responses per physician). Prevalence rates of 30 rare lung
diseases are reported.
Conclusions: A multi-disease rare lung disease registry was implemented in the Australian and New Zealand
health care settings that provided prevalence data on orphan lung diseases in this region but was limited by
under reporting.
Keywords: Rare diseases, Lung disease, Registries, Prevalence, Australia, New Zealand

Background
The Australian Therapeutic Goods Authority defines
an orphan disease as “a rare disease, or condition,
likely to affect not more than 2,000 individuals in
Australia at any time” [1] , while in Europe it is defined as affecting less than 1 in 2000 people [2].
Despite individual diseases affecting only a small
number of people, orphan diseases collectively contribute a significant portion of the overall burden of
disease [3]. European studies estimate that one in
three cases of severe disability in children is caused
by a rare disease and combined, their prevalence is
* Correspondence: Frauleinkarly@gmail.com
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6–10 % in the general population [4]. This would equate
to approximately 1.2 million Australians, however definitive epidemiological data in the Australian population are
limited [4, 5].
Orphan diseases may be varied in nature but they face
similar barriers to their research and treatment development. Specifically, rare lung diseases are difficult to study
because they are a heterogeneous group of diseases that
often do not have a formal description in the International
Classification of Diseases (ICD-10) [6, 7] , and in some
cases, may be extremely rare. Defining cases for trials can
be a challenge due to delayed diagnoses and poor clarity
in diagnostic criteria [8]. Furthermore, poorly defined
clinical endpoints can increase the cost of clinical trials
[9]. Historically low cost-benefit values have been a major
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disincentive for pharmaceutical companies to invest in
rare disease research [10], a factor that is now being mitigated by Orphan Drug legislation, developed in the US in
2002 [11], in Australia in 1998 [1] and the EU in 2000
[12]. More recently, initiatives such as the Creating Hope
Act, passed as part of the Food and Drug Administrative
Safety and Innovation Act in 2012 in the USA are aimed
at enhancing drug discovery for people with a rare disease
[13] by subsidising research and trials. In order to qualify
for these schemes, disease specific prevalence data are essential to define qualifying diseases. Some pulmonary
disease-specific registries have been successful internationally in providing these data; for example the Alpha One
International Registry (AIR) [14] and Cystic Fibrosis
Registries [15].
Despite being developed countries, Australia and
New Zealand have unique characteristics in their
population density distribution; their relatively small
populations are dispersed over a large geographical
area bringing further challenges to collaborative studies involving patients with rare and extremely rare
diseases. In Australia, three National lung disease specific registries exist; the Australian CF Data Registry
[16] and the relatively new Australian Idiopathic Pulmonary Fibrosis Registry [17] and Australian Bronchiectasis Registry.
Because of the urgent need for epidemiological data
on rare lung diseases to support research funding
and drug development in Australia and New Zealand
we investigated the feasibility of using a single lung
disease registry based on the web-based British
Paediatric Orphan Lung Disease Registry (BPOLD)
[18] to provide prevalence data for multiple orphan
lung diseases in both the paediatric and adult
population.

Methods
This was a descriptive population-based study. A webbased registry entitled the Australasian Registry Network
of Orphan Lung Diseases (ARNOLD) was established
based on the model of BPOLD [18]. The ARNOLD
website was created with Dreamweaver CS3 software
(http://www.adobe.com) using HyperText Markup Language
plus PHP scripting language (www.php.net). It was uploaded
to a commercial server (www.siteground.com). All adult and
paediatric respiratory physicians in Australia and New
Zealand who were members of the Thoracic Society of
Australia and New Zealand were invited to participate
between July 2009 and June 2014. Initially quarterly emails
were sent to Australian physicians until April 2011, after
which emails were sent monthly. New Zealand physicians
were invited to participate from 2011 with monthly
emails. Members of the Pulmonary Interstitial Vascular
Organisational Taskforce (PIVOT) of Lung Foundation
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Australia agreed on the inclusion of 30 rare lung
diseases following face-to-face meetings and email
correspondence ensuring a mixture of paediatric and
adult diseases. Non cystic fibrosis bronchiectasis was
not included as it was felt not to be an orphan disease
in Australia and New Zealand.
Individual physicians were asked to respond via a simple
link embedded within the email indicating whether they
had or had not seen a patient (“nothing to report”) with
one of the rare lung diseases in the previous month. If
they answered in the affirmative they were automatically
directed to the ARNOLD website and asked to enter the
following details: reported disease (mandatory), patient
initials, date of birth (DOB), postcode, medical record
number and whether this was a “new case” or “follow-up”
(all non-mandatory fields). Physician details, time and date
were also logged automatically through the email link. Input rules such as mandatory fields and drop-down menus
were developed to ensure high quality data. These details
were transmitted securely using Secure Socket Layer
(SSL), further encrypted using the MySQL ENCODE
function (http://dev.mysql.com/doc/refman/5.1/en/encry
ption-functions.html#function_encode) and data were
stored in a MySQL database located on the server.
Statistical analyses were performed using Microsoft
Excel and Microsoft Access software. Queries were
used to first separate responses from Australian and
New Zealand physicians and then paediatric and adult
physicians. Duplicate data for the same patient were
isolated by identifying records with a matching
disease, patient initials, suburb and DOB and subsequently excluded from final calculations. Prevalence
was calculated by dividing the total number of reports
for each disease by the population estimates for 0–18
year-olds for paediatrics and older than 19 years old
for adults for 2014 using data from the Australian
Bureau of Statistics and Statistics New Zealand [19,
20]. This was then expressed as prevalence per
million population over the 5 year study period.
Ethics

This study was approved by the South Eastern Sydney
Illawarra Area Heath Service Network Human Research
Ethics committee for Australia (08/187) and the Multiregion Ethics Committee (MEC/11/03/026) for New
Zealand.

Results
Email invitations were sent to 649 Australian respiratory physicians and 65 in New Zealand. In response
to approximately 32,300 emails, 231 (32.4 %) physicians responded to subsequent emails a total of 1554
times (4.8 % response rate). We received an average
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6.73 responses per physician and an average of 33
responses per month. Thirty two participants (14 %)
responded 13 or more times, 16 (7 %) responded
10–12 times, 24 (10 %) responded 7–9 times, 40
(17 %) responded 6–8 times and 118 (51 %)
responded 1–3 times. Forty three paediatric physicians gave a total of 455 responses (average 10.6
responses per physician) and 188 adult physicians
responded a total of 1099 times (average 5.8
responses per physician).
Participants responded with “nothing to report” a
total of 1131 times (73 % of responses). In the positive responses there were five incidences of matching
initials, postcode, DOB and disease and these were
excluded from the final calculations as duplicates;
however it is noted that 273 notifications (65 %) had
missing patient identifiers. The status of ‘new diagnosis’ vs ‘follow up’ was reported on for 194 reports

(46 %). Disease prevalence in Australia is listed in
Table 1 and New Zealand in Table 2.

Discussion
This study has demonstrated proof-of-concept that it
is possible to use an online web based registry to aggregate numbers to create national prevalence data on
30 rare lung diseases in Australia and New Zealand.
However physician engagement was low (32.4 %) indicating that the actual national prevalence rates are
likely to be higher than reported.
Compared to single disease registries, those that
collect data on multiple diseases have the benefit of
cost-effectiveness, standardisation of data, and ease of
use [21–23]. They capture information on many rare
diseases that are potentially absent or misclassified in
the ICD10 [7] and thus are not adequately registered by

Table 1 Prevalence of rare lung diseases in Australia between 2009 and 2014– paediatric, adult and general population
Disease

Paediatric
No. of reports

Adult
Prevalence
per million

No. of reports

Total population
Prevalence
per million

No. of reports

Prevalence
per million

Acute idiopathic eosinophilic pneumonia

1

0.18

2

0.12

3

0.13

Children’s interstitial lung disease (ChILD)

21

3.80

0

0.00

21

0.92

Chronic idiopathic eosinophilic pneumonia

0

0.00

7

0.40

7

0.31

Churg-Strauss vasculitis

0

0.00

9

0.52

9

0.39

Congenital Malformations of the Trachea

4

0.72

0

0.00

4

0.18

Cryptogenic organising pneumonia

0

0.00

21

1.21

21

0.92

Cystic lung lesions

12

2.17

5

0.29

17

0.74

Diaphragmatic Hernia

1

0.18

2

0.12

3

0.13

Diffuse panbronchiolitis

0

0.00

1

0.06

1

0.04

Drug reactions with eosinophilia

0

0.00

2

0.12

2

0.09

Extrinsic allergic alveolitis

0

0.00

16

0.93

16

0.70

Follicular bronchiolitis

1

0.18

0

0.00

1

0.04

Goodpasture syndrome

0

0.00

3

0.17

3

0.13

Hereditory haemorrhagic ataxia telangiectasia

0

0.00

7

0.40

7

0.31

Idiopathic pulmonary haemosiderosis

5

0.90

4

0.23

9

0.39

Langerhans cell histiocytosis

0

0.00

7

0.40

7

0.31

Lobar emphysema

7

1.27

1

0.06

8

0.35

Lymphangioleiomyomatosis

0

0.00

2

0.12

2

0.09

Obliterative bronchiolitis (not transplant related)

5

0.90

3

0.17

8

0.35

Other vasculitides incl. microscopic polyangiitis

1

0.18

7

0.40

8

0.35

Primary ciliary dyskinesia

4

0.72

2

0.12

6

0.26

Pulmonary alveolar proteinosis

3

0.54

5

0.29

8

0.35

Pulmonary amyloidosis

0

0.00

1

0.06

1

0.04

Tracheo-oesophageal fistula

4

0.72

1

0.06

5

0.22

Granulomatosis with polyangiitis

2

0.36

Totals

71

12.82

7

0.40

9

0.39

115

6.65

186

8.13
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Table 2 Prevalence of rare lung diseases in New Zealand between 2009 and 2014– general population
Disease

No. of reports

Acute idiopathic eosinophilic pneumonia

0

Per million
0.00

Children’s interstitial lung disease (ChILD)

0

0.00

Chronic idiopathic eosinophilic pneumonia

0

0.00

Churg-Strauss vasculitis

1

0.22

Congenital Malformations - Trachea

0

0.00

Cryptogenic organising pneumonia

2

0.44

Cystic lung lesions

1

0.22

Diaphragmatic Hernia

0

0.00

Diffuse panbronchiolitis

2

0.44

Drug reactions with eosinophilia

0

0.00

Extrinsic allergic alveolitis

3

0.66

Follicular bronchiolitis

0

0.00

Goodpasture syndrome

0

0.00

Hereditory haemorrhagic ataxia telangiectasia

0

0.00

Idiopathic pulmonary hemosiderosis

1

0.22

Langerhans cell histiocytosis

0

0.00

Lobar emphysema

0

0.00

Lymphangioleiomyomatosis

0

0.00

Obliterative bronchiolitis (not transplant related)

0

0.00

Other vasculitides incl. microscopic polyangiitis

1

0.22

Primary ciliary dyskinesia

3

0.66

Pulmonary alveolar proteinosis

0

0.00

Pulmonary amyloidosis

0

0.00

Tracheo-oesophageal fistula

0

0.00

Granulomatosis with polyangiitis

0

0.00

Total

14

3.10

existing health systems. The Australian Federal and State
Governments signed a National Health Information
Agreement (NHIA) in 2013 [24] committing to better
health information collection and dissemination. This
registry therefore fills an important gap in collecting
prevalence statistics in the Australian population and
fulfils the objectives of the NHIA and represents the
only prevalence data that exist for these diseases in
Australia and New Zealand.
ARNOLD translated smoothly to the Australian and
New Zealand healthcare settings from the already established UK BPOLD registry. In addition to being cost-effective, it is relatively simple to use with the functionality
of a one-click secure reply. Input rules ensured that data
entry was uniform and very little data maintenance was
necessary. The EU Committee of Experts on Rare Diseases
(EUCERD) recently convened to develop a set of core
recommendations for rare disease registry design. They
highlighted the need for easy exchange of data on an

international level and a common standard of data collection [23], both of which are import features of the
BPOLD/ARNOLD design.
The registry however faced a number of barriers.
The data were limited by under-reporting of patient
identifiers and other non-mandatory details. Only
35 % of notifications included details about postcode,
DOB or patient initials, meaning that possible duplicate notifications could not be identified for the majority of the reports. This may have led to overreporting of some rare conditions. Also, there were
insufficient DOB data to distinguish paediatric and
adult patients and so prevalence calculations were
made by identifying the person reporting as either a
paediatric or adult physician and we acknowledge that
this may have limited the accuracy. The benefit of
this information is that it gives an indication of the
workload of paediatric physicians compared to adult
physicians for these rare diseases.
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The system has the capability of recording incidence data, however the ‘new diagnosis’ status was
only recorded in 46 % of cases. This meant that the
majority of cases could not be differentiated into
new or existing diagnoses and incidence calculations
could not be performed. Many of these limitations
could be remedied by making more boxes mandatory
at the data entry phase in the future, however it may
compromise the system’s usability. A further limitation is the low response rate; of a possible 714 adult
and paediatric physicians only 231 physicians
(32.4 %) responded in contrast to the UK BPOLD
where 64 % of physicians responded [18]. We speculate that one of the reasons the response rate of the
UK BPOLD is higher than ARNOLD is that it involved only respiratory paediatrician respondents;
paediatricians have been responding to monthly requests to report children with rare diseases since the
establishment of the British Paediatric Surveillance
Unit in 1986 [25] and as such, it is likely that they
were more inclined to respond to requests to report
monthly data compared to adult physicians. The
Australian Paediatric Surveillance Unit [26] was
established over 20 years ago and has a monthly response rate of approximately 95 % no such system
exists for adult physicians.
Furthermore, it is possible that the list of invited
physicians in ARNOLD contained many trainees who
do not see rare lung disease patients in a clinic setting or that time pressures prevailed in a busy clinic
setting thus creating a significant barrier to reporting
patients to the registry.
A registry integrated with electronic medical records could bring efficiencies and would prevent
overburdening busy clinicians, however the current
systems depend on ICD-10 classifications from which
many rare lung diseases are missing. This would also
have ethical implications in gaining consent and the
data would have to be completely de-identified before
being collected by our database.
A final limitation was that specific disease definitions
were not provided to reporting physicians and relied on
individual physician diagnoses so there may have been
some inconsistencies in reporting. Although this can be
easily addressed for many rare lung diseases, for many
rare lung diseases consensus opinion has not yet been
reached on the diagnostic criteria and this is an enduring
limitation in rare disease research.
The prevalence rates for each of the 30 rare lung
diseases reported in this study are much lower than
reported rates in other countries. For example, pulmonary alveolar proteinosis was found to have a
prevalence of 0.35 per million in Australia, 3 per million in the BPOLD study [18] and between 4 and 40
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per million internationally. The same pattern was
seen consistently across many diseases. No cases were
reported in New Zealand for 17 of 30 conditions.
This could represent a genuinely lower rate of rare
diseases in the Australasian population but it is more
likely a reflection of low reporting rates from the
comparatively low population of Australia and New
Zealand.
In contrast, registries of single orphan lung diseases
have had greater physician engagement. The Australian
Idiopathic Pulmonary Fibrosis Registry has data on
more than 600 patients since its establishment [17].
A key feature of its success is that each State and
Territory in Australia has a research coordinator
whose responsibility it is to aid physicians in entering
the data onto the registry. Other successful examples
of single orphan lung disease registries include cystic
fibrosis [15] and, more recently children with interstitial lung disease (chILD) in the USA [27] and in the
European Union (EU) [28]. A recent qualitative study
that sought consensus opinions of 41 multidisciplinary rare disease experts highlighted need for physicians be convinced of the importance of rare disease
registries in promoting and enhancing clinical research [29].
Despite these limitations, we have demonstrated
that many physicians recognise the importance of
contributing to a web-based rare disease registry
which will help standardise care and allow for research. Even with low reporting, ARNOLD has provided data, for the first time, of the prevalence of
patients with rare lung diseases in Australia and
New Zealand. An important advantage of this multidisease approach is that it is highly suitable for gathering data on extremely rare orphan diseases where
there is no capacity to establish disease specific
registries.

Conclusions
We have demonstrated a proof of concept that it is
feasible to obtain National data on the prevalence of
multiple rare and extremely rare lung diseases using a
web-based registry in Australia and New Zealand. These
data will be important to pharmaceutical companies
undertaking orphan drug development in Australasia
and it will help define research priorities to benefit
those many people living with a rare lung disease. The
next step is to first evaluate the registry in order to
understand how best to improve reporting and then
adequately invest in this type of web-based registry
approach to address the reporting barriers, increase
awareness, aid data input to improve the accuracy of
the data and make it sustainable.
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